Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations

Next Previous
Trial Profile

Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicapone (Primary) ; Antiparkinsonians; Decarboxylase inhibitors; Entacapone; Levodopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms OPTIPARK; OPTIPARK_V1
  • Sponsors Bial; BIAL - Portela C S.A.

    • Most Recent Events

    • 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
    • 22 Sep 2021 Results assessing opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson's disease (PD) patients with motor fluctuations, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
    • 22 Sep 2021 Results of post-hoc analysis assessing the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson's disease (PD) treated in real-world conditions, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top